Table 4.
Characteristics of subjects with inconsistent IGRA results over the 4-week study period
| Subject no. | Age (yr) | Sexc | TB risk | IGRA | Result from visit (study day)d: |
Overall trenda | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 (0) | 2 (+7) | 3 (+14) | 4 (+21) | 5 (+28) | ||||||
| 7 | 41 | M | Medium | QFT | Positive (0.45) | Positive (1.05) | Negative (0.00) | Negative (0.00) | Inconsistent | |
| T-SPOT | Negative (1/0) | Negative (0/0) | Negative (0/0) | Negative (4/1) | Negative | |||||
| 8 | 42 | F | Low | QFT | Positive (0.49)b | Negative (0.00) | Negative (0.00) | Negative (0.00) | Negative (0.00) | Inconsistent |
| T-SPOT | Negative (0/0) | Negative (1/0) | Negative (0/0) | Negative (0/0) | Negative (0/0) | Negative | ||||
| 12 | 34 | F | Low | QFT | Negative (0.00) | Positive (2.58) | Negative (0.00) | Negative (0.01) | Negative (0.00) | Inconsistent |
| T-SPOT | Negative (0/0) | Negative (0/0) | Negative (1/1) | Negative (0/0) | Negative (0/0) | Negative | ||||
| 13 | 48 | F | Low | QFT | Negative (0.00) | Positive (1.09) | Negative (0.00) | Negative (0.00) | Inconsistent | |
| T-SPOT | Negative (1/1) | Negative (1/0) | Negative (1/0) | Negative (0/2) | Negative | |||||
| 14 | 39 | F | Low | QFT | Negative (0.00) | Positive (0.82) | Negative (0.02) | Negative (0.00) | Inconsistent | |
| T-SPOT | Negative (0/3) | Negative (1/1) | Negative (2/2) | Negative (2/2) | Negative | |||||
| 17 | 48 | F | Low | QFT | Positive (0.59)b | Negative (0.20) | Negative (0.11) | Negative (0.19) | Negative (0.31) | Inconsistent |
| T-SPOT | Negative (0/3) | Negative (1/1) | Negative (0/3) | Negative (0/5) | Negative (0/3) | Negative | ||||
| 19 | 20 | M | Low | QFT | Positive (0.77) | Negative (0.08) | Negative (0.00) | Negative (0.00) | Negative (0.00) | Inconsistent |
| T-SPOT | Negative (0/0) | Negative (0/0) | Negative (0/0) | Negative (0/0) | Negative (0/0) | Negative | ||||
| 22 | 47 | F | Medium | QFT | Negative (0.28) | Negative (0.00) | Negative (0.10) | Negative (0.09) | Negative | |
| T-SPOT | Positive (1/10) | Positive (0/8) | Negative (0/5) | Negative (0/2) | Inconsistent | |||||
| 24 | 49 | F | Medium | QFT | Positive (0.37)b | Negative(0.20) | Negative (0.21) | Negative (0.26) | Inconsistent | |
| T-SPOT | Negative (0/2) | Negative (0/3) | Negative (5/0) | Negative (0/3) | Negative | |||||
| 25 | 41 | M | Medium | QFT | Positive (0.60) | Positive (0.49) | Positive (1.63) | Positive (0.62) | Positive (0.64) | Positive |
| T-SPOT | Positive (100/30) | Positive (100/100) | Negative (0/1) | Negative (3/0) | Negative (3/0) | Inconsistent | ||||
| 26 | 48 | F | Low | QFT | Negative (0.26) | Positive (0.52)b | Negative (0.33) | Negative (0.14) | Inconsistent | |
| T-SPOT | Positive (0/8) | Positive (2/24) | Positive (0/6) | Positive (3/14) | Positive | |||||
| 27 | 44 | F | Medium | QFT | Positive (1.04) | Positive (0.61) | Positive (1.66) | Positive (0.96) | Negative (0.24)b | Inconsistent |
| T-SPOT | Positive (5/10) | Positive (12/15) | Positive (4/10) | Positive (14/17) | Positive (13/10) | Positive | ||||
| 32 | 55 | F | Medium | QFT | Negative (0.19) | Negative (0.03) | Negative (0.12) | Negative (0.26) | Negative | |
| T-SPOT | Positive (8/4)b | Positive (6/0) | Negative (2/0) | Negative (3/1) | Inconsistent | |||||
a
Conversions were defined as a baseline IFN-γ concentration of <0.35 IU/ml, followed by an increase across the threshold of ≥0.35 IU/ml. Reversions were defined as the opposite progression.
b
IFN-γ responses within proposed borderline zones from 0.2 to 0.7 IU/ml and 4 to 8 SFCs which showed changes in results from negative to positive or vice versa according to the manufacturers' thresholds.
c
M, male; F, female.
d
Values in parentheses represent IFN-γ responses in IU/ml and SFCs (ESAT-6 panel/CFP-10 panel) for the QFT and the T-SPOT assay, respectively.